"Receiving regulatory clearance to move into clinical studies for JDP-205 is a significant milestone for the company."
Lansdale, PA (PRWEB) April 14, 2011
JDP Therapeutics, Inc., a specialty pharmaceutical company, announced today that regulatory authorities have accepted JDP’s clinical trial application for its Investigational New Drug to begin human clinical trials and to evaluate the safety, tolerability, and pharmacokinetic properties of the company's lead product, JDP-205. "Receiving regulatory clearance and the no-objection-letter to move into clinical studies for JDP-205 is a significant milestone for the company," said Jie Du, Ph.D. President of JDP Therapeutics Inc.
JDP’s first program, JDP-205 is a proprietary product being developed for the treatment of allergic reactions for the hospital market. A survey of 110 physicians revealed that 86% of responding doctors had indicated readiness to use JDP-205 when it is approved by the FDA. A second independent study with in-depth clinician interviews confirmed the findings.
Allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates but with very limited selections of medications. JDP-205 will offer an alternative treatment to the current therapy for the first time in over 55 years.
JDP Therapeutics Inc., founded in 2008, is a specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for acute care use in the hospital setting.
For further information, please call 215-661-8557 or email info(at)jdptherapeutics(dot)com